More PMA information:
PMA is a substrate for CYP2D6 enzyme, like ie. MDMA.
A CYP2D6-deficient test subject was observed to excrete 4.4%
of a 5 mg oral dose of PMA as 4-hydroxyamphetamine, compared
to 49 and 64% excreted as this metabolite in two normal subjects.
In addition to this metabolite, both normal subjects small
amounts of 1-(4-methoxyphenyl)propan-2-one and 4-hydroxynorephedrine.
By contrast, CYP2D6 deficient subject excreted, in addition to
small amounts of 4-hydroxyamphetamine, a relatively large
amount of 1-(4-methoxyphenyl)propan-2-one oxime as well as the
ketone itself. 4-hydroxy- and 4-methoxybenzoic acid were also
detectable, unlike in two other subjects. All three subjects
excreted a small amount of an unidentified metabolite.
This shows that PMA metabolism can vary from individual to
individual, which can have important implications, particulary
in relation to variations in response to the drug.
References:
Kitchen I, Tremblay J, Andre J, Dring LG, Idle JR, Smith RL, Williams RT.
Interindividual and interspecies variation in the metabolism of the hallucinogen
4-methoxyamphetamine. Xenobiotica. 1979;9(7):397-404.
Wu D, Otton SV, Inaba T, Kalow W, Sellers EM.
Interactions of amphetamine analogs with human liver CYP2D6.
Biochem Pharmacol. 1997;53(11):1605-12.